[팜뉴스=이권구 기자] Curatis (CEO Cho Kwan-gu) held a press conference in Yeouido on the 26th and announced its growth strategy and vision following listing on the KOSDAQ market.
Founded in 2016, Quratis is a company specializing in the development of immune-related vaccines, and is engaged in contract manufacturing (CMO) and contract development and manufacturing (CDMO) businesses.
Currently, the main development items are ‘QTP101’, an adult and adolescent tuberculosis vaccine, and ‘QTP104’, a next-generation COVID-19 mRNA vaccine. QTP101 completed phase 2a clinical trials for adults and phase 1 clinical trials for adolescents in Korea in 2021, and received IND approval for global integrated phase 2b/3 from the Food and Drug Safety Administration last year. QTP104 is currently completing phase 1 clinical trials in Korea.
According to Curatis, QTP101, which is being developed, is a tuberculosis vaccine for adults and adolescents. It boosts the body’s immune response formed by BCG and can prevent tuberculosis with just three vaccinations. It is a ‘Subunit Vaccine’ from which specific antigens are extracted, and is characterized by its high safety.
QTP101 is designed to optimize its function through a combination of antigen (ID93), including three virulence and one latent, selected based on bioinformatics analysis, and ‘GLA-SE’, an immune enhancer which improves immunity. a product that stimulates immune cells such as monocytes and macrophages that are part of the innate immune response to elicit an immune response and increase the effect.
The company is promoting the business with the aim of commercializing QTP101 globally in 2025, and plans to establish a joint promotion system with domestic pharmaceutical companies and enter a total of 44 countries, mainly Indonesia and China.
In addition to the main pipeline, the next generation tuberculosis vaccine ‘QTP102’ is in the clinical development stage, and the schistosomiasis vaccine ‘QTP105’ is undergoing phase 1 clinical trials abroad.
In 2020, Curatis established a bio research institute and bio factory at Osong High-tech Medical Center in Chungcheongbuk-do and set up its own production infrastructure at the GMP qualification level in the United States, Europe and Korea, and operates CMO and Business CDMO based on this.
The company explained that Osong Bio Plant is capable of producing 50 million vials of liquid and freeze-dried injectables per year. In the future, after completing the development of its own vaccine, it plans to supply the vaccine to the market through Osong Bio Plant’s production infrastructure.
At the meeting, Kwan-gu Cho, CEO of Curatis, said, “We are confident in continued growth based on the commercialization of QTP101 and QTP104, which are our main pipelines, and the CMO∙CDMO business.” We will work hard to develop a vaccine,” he said.
The total number of shares offered for public offering is 3,500,000 shares, and the expected offering price per share is 6,500 won to 8,000 won. The company plans to raise up to KRW 28 billion through a public offering, and the funds raised will be used for phase 2b/3 clinical trials of QTP101.
Aiming to enter the KOSDAQ in June, the company is holding demand forecasts from institutional investors from the 30th to the 31st, setting the public offering price, and accepting general subscriptions on June 5th and 7th. Daishin Securities and Shinyoung Securities are jointly responsible for the lead manager.
